tiprankstipranks
Advertisement
Advertisement

ACRS Stock Latest News

Aclaris Therapeutics: Advancing Immunology Pipeline and Strong Cash Position Support Reiterated Buy, Unchanged $16 Price Target
RatingsAclaris Therapeutics: Advancing Immunology Pipeline and Strong Cash Position Support Reiterated Buy, Unchanged $16 Price Target
21d ago
ACRS
Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)
PremiumThe Fly
Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)
25d ago
ACRS
Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)
PremiumThe Fly
Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)
25d ago
ACRS
Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler
PremiumThe Fly
Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler
27d ago
ACRS
Aclaris Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
Aclaris Therapeutics initiated with a Buy at Guggenheim
27d ago
ACRS
Aclaris Therapeutics initiated with a Buy at Guggenheim
PremiumThe FlyAclaris Therapeutics initiated with a Buy at Guggenheim
27d ago
ACRS
Aclaris Therapeutics price target raised to $10 from $8 at Wedbush
Premium
The Fly
Aclaris Therapeutics price target raised to $10 from $8 at Wedbush
1M ago
ACRS
Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial
Premium
The Fly
Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial
1M ago
ACRS
Aclaris Reports Positive ATI-052 Phase 1a Trial Results
PremiumCompany Announcements
Aclaris Reports Positive ATI-052 Phase 1a Trial Results
1M ago
8K
ACRS
Aclaris Therapeutics management to meet virtually with Craig-Hallum
PremiumThe Fly
Aclaris Therapeutics management to meet virtually with Craig-Hallum
1M ago
ACRS
3 ‘Strong Buy’ Stocks With Up to 180% Upside to Buy Now, According to Top Analysts, 4/16/2026
PremiumMarket News
3 ‘Strong Buy’ Stocks With Up to 180% Upside to Buy Now, According to Top Analysts, 4/16/2026
2M ago
ACRS
KALV
Aclaris Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe Fly
Aclaris Therapeutics initiated with an Outperform at Oppenheimer
2M ago
ACRS
Aclaris Therapeutics: Advancing ATI-052 and Bosakitug Pipeline Underpins Buy Rating and $16 Price Target
PremiumRatingsAclaris Therapeutics: Advancing ATI-052 and Bosakitug Pipeline Underpins Buy Rating and $16 Price Target
2M ago
ACRS
Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO
Premium
The Fly
Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO
2M ago
ACRS
CRDF
Aclaris Therapeutics completes patient enrollment in Phase 2 trial of bosakitug
Premium
The Fly
Aclaris Therapeutics completes patient enrollment in Phase 2 trial of bosakitug
2M ago
ACRS
Helus Pharma appoints Conwell as Chief People Officer
PremiumThe Fly
Helus Pharma appoints Conwell as Chief People Officer
3M ago
ACRS
HELP
Aclaris Therapeutics Raises $20 Million in Equity Financing
PremiumCompany Announcements
Aclaris Therapeutics Raises $20 Million in Equity Financing
3M ago
8K
ACRS
Aclaris Therapeutics Raises Capital via Institutional Stock Sale
PremiumCompany Announcements
Aclaris Therapeutics Raises Capital via Institutional Stock Sale
3M ago
8K
ACRS
Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)
PremiumThe Fly
Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)
3M ago
ACRS
Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)
PremiumThe FlyAclaris Therapeutics reports Q4 EPS (16c), consensus (14c)
3M ago
ACRS
Aclaris Therapeutics initiates Phase 1b PoC trial of ATI-052
Premium
The Fly
Aclaris Therapeutics initiates Phase 1b PoC trial of ATI-052
3M ago
ACRS
Aclaris Therapeutics initiated with a Buy at Craig-Hallum
Premium
The Fly
Aclaris Therapeutics initiated with a Buy at Craig-Hallum
4M ago
ACRS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >